A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

  • Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Hepatocellular Carcinoma (HCC)
  • Bladder Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Ansan-si
  • Anyang
  • Bucheon
  • Bucheon-si
  • Busan
  • Cheongju-si
  • Chuncheon
  • Chuncheon-si
  • Daegu
  • Daejeon
  • Euijeongbu
  • gangneung
  • Gwangju
  • Hwaseong-si
  • Iksan
  • Jeonju
  • Seongnam-si
  • Seoul
  • Suwon
  • Ulsan
  • Wonju-si
  • Yangsan
Trial Identifier:

NCT03232593 ML39313

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

      Hoffmann-La Roche Sponsor
      NCT03232593,ML39313 Trial Identifier
      Atezolizumab Treatments
      Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma, Hepatocellular Carcinoma Condition
      Official Title

      Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)

      Eligibility Criteria

      All Gender
      No Healthy Volunteers
      Inclusion Criteria
      • Participants who are administered with atezolizumab for the locally approved indications
      Exclusion Criteria
      • Participants with a known hypersensitivity to atezolizumab or to any of the excipients

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now